Video

Dr. Kaplan on Real-World Surgical Retreatment Rates in LUTS/BPH

Steven Kaplan, MD, discusses real-world surgical retreatment rates in patients with lower urinary tract symptoms/benign prostatic hyperplasia.

Steven Kaplan, MD, professor of Urology, Icahn School of Medicine at Mount Sinai, discusses real-world surgical retreatment rates in patients with lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH).

Results from a study presented during the 2021 AUA Annual Meeting showed that real-world surgical retreatment rates are higher than what has previously been reported in this patient population, according to Kaplan. This is true even for standard procedures, such as transurethral resection of the prostate (TURP).

Results included that compared with TURP, GreenLight, and UroLift, patients who received Rezum steam injection experienced the highest rates of surgical retreatment in 1 year, Kaplan says.

These real-world data are important, as they may possess the potential to inform treatment decisions for these patients, Kaplan concludes. 

Related Videos
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Binod Dhakal, MD
Sheldon M. Feldman, MD
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD